| Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration ER Burnight, M Gupta, LA Wiley, KR Anfinson, A Tran, R Triboulet, ... Molecular Therapy 25 (9), 1999-2013, 2017 | 154 | 2017 |
| Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials EY Chen, SK Joshi, A Tran, V Prasad JAMA internal medicine 179 (5), 642-647, 2019 | 100 | 2019 |
| The role of low-energy (≤ 20 eV) electrons in astrochemistry MC Boyer, N Rivas, AA Tran, CA Verish, CR Arumainayagam Surface Science 652, 26-32, 2016 | 86 | 2016 |
| Morphological and molecular defects in human three-dimensional retinal organoid model of X-linked juvenile retinoschisis KC Huang, ML Wang, SJ Chen, JC Kuo, WJ Wang, PNN Nguyen, ... Stem Cell Reports 13 (5), 906-923, 2019 | 73 | 2019 |
| Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy AA Tran, V Prasad The Lancet Oncology 21 (9), 1134-1136, 2020 | 30 | 2020 |
| Phase I trials and therapeutic intent in the age of precision oncology: what is a patient's chance of response? DL Tao, T Kartika, A Tran, V Prasad European Journal of Cancer 139, 20-26, 2020 | 12 | 2020 |
| Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis A Tran, Q Klossner, T Crain, V Prasad BMJ open 10 (6), e036357, 2020 | 12 | 2020 |
| Rapid mobilization of medical students to provide health care workers with emergency childcare during the COVID-19 pandemic ECA Lane, AA Tran, CJ Graulty, T Bumsted Academic Medicine 96 (9), 1302-1305, 2021 | 8 | 2021 |
| Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Intern Med. 2019; 179 (5): 642–647 EY Chen, SK Joshi, A Tran, V Prasad | 8 | 2018 |
| Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia AA Tran, M Miljković, V Prasad Leukemia Research 96, 106420, 2020 | 4 | 2020 |
| Replacing the NCCN’s blocks with wheels: how should consideration of societal spending be incorporated into oncology practice? AA Tran, V Prasad Pharmacoeconomics 38, 729-731, 2020 | 2 | 2020 |
| Drug repurposing in oncology–Authors' reply AA Tran, V Prasad The Lancet Oncology 21 (12), e544, 2020 | 1 | 2020 |
| Visualizing the randomized sham-controlled trial in orthopedic research: proposed steps to conducting a total knee arthroplasty randomized controlled trial AA Tran, V Prasad Journal of comparative effectiveness research 12 (3), e210275, 2023 | | 2023 |
| Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” A Tran, V Prasad PharmacoEconomics 38, 895-896, 2020 | | 2020 |
| Modeling partial lipodystrophy using human pluripotent stem-cell derived CIDE-C E186X mutant adipocytes AA Tran Wellesley College, 2015 | | 2015 |
| Designing a new ultrahigh vacuum chamber optimized for astrochemical studies N Rivas, AA Tran, C Arumainayagam ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 245, 2013 | | 2013 |
